Including anticancer agents is considered acceptable when patients have numerous lymph node metastases (irrespective of tumor subtype), if their cancer is ER- and/or PgR-positive and expressing a low level of Ki67. This evidence concerns the gene ESR1 and metastatic malignant neoplasm in the lymph nodes.